Transarterial Chemoembolization (TACE) Plus Bevacizumab for Liver Metastases
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Bevacizumab.
- Who it may be relevant to
- Registry conditions: Cancer, Metastatic Cancer, Liver Metastases. Basic parameters: 18 years — 80 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Iran
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
An Open-Label Pilot Study to Evaluate Efficacy and Safety of Bevacizumab Via Transarterial Chemoembolization (TACE) in Patients With Liver Metastases
Overview
Trans arterial chemoembolization (TACE) has emerged as a treatment option for chemotherapy-refractory diseases in Liver metastases. By delivering chemotherapy agents directly to the tumor site, TACE can maximize local drug concentrations and reduce systemic adverse reactions. Bevacizumab is a monoclonal antibody that functions as an angiogenesis inhibitor. It works by slowing the growth of new blood vessels by inhibiting vascular endothelial growth factor A (VEGF-A). The application of Bevacizumab during TACE has not been reported. In this study, we will evaluate the the overall survival (OS)、efficacy, and safety of the application of Bevacizumab during TACE in patients with Liver Metastases by designing an open, single-arm phase II clinical study.
Interventions
- Drug Bevacizumab
Infusion of Bevacizumab-loaded hepaspher through transarterial chemoembolization.
Primary outcome measures
- Overall Survival Rate [Time frame: 6 months]
- Objective response rate [Time frame: 6 months]
Secondary outcome measures (1)
- Adverse event [Time frame: 6 months]
Eligibility criteria
Inclusion criteria
- Confirmation of metastatic liver cancer via histological examination or a characteristic imaging profile on dynamic computed tomography (CT) scan or magnetic resonance imaging (MRI) without indications for surgical resection
- Eastern cooperative oncology group performance status (ECOGPS) of 0 or 1
- Liver function categorized as Child-Pugh class A or B
- Stable non-hepatic metastases, such as skeletal, pulmonary, or lymph node metastases
- Hepatic tumor burden below 70%
- Expected survival duration exceeding six months
- Laboratory findings meeting specific criteria, including platelet count >50×109 /L, hemoglobin >8.0 g/dL, ANC count ≥1.5 × 109/L, bilirubin <51 mmol/L, alanine and aspartate aminotransferase <3 times the upper limit of the normal range, and serum creatinine <1.5 times the upper limit of the normal range.
Exclusion criteria
- Active infection
- Presence of severe comorbidities, such as hepatic encephalopathy, refractory ascites, and esophageal variceal bleeding
- Prior liver resection
- Previous TACE therapy received at other healthcare facilities
- Poor performance status (ECOGPS > 1)
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- N/A
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
Iran · 1 center
- Pardis Noor Medical Imaging and Cancer Center — Tehran
Identifiers
NCT: NCT06311851 · PNCC140201